The Patent Finder

Biogen Idec Inc.

Also on record
Records under this name other than patents Biogen Idec Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Biogen Idec Inc.

PatentTitleStatus Expires Confidence
US 8,608,960Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Formerly held
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 9,198,955Method for Reducing Flu-Like Symptoms Associated with Intramuscular Administration of Interferon Using a Fast Titration Escalating Dosing Regimen
Formerly held
In force
 · High confidence
In forceHigh confidence
US 7,759,117Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Formerly held
Term ended
Term ended Feb 6, 2026 · From the USPTO record
Term endedTerm ended Feb 6, 2026From the USPTO record
US 7,157,276Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Formerly held
Term ended
Term ended Jun 21, 2024 · From the USPTO record
Term endedTerm ended Jun 21, 2024From the USPTO record
US 7,531,174Cripto Blocking Antibodies and Uses Thereof
Formerly held
Term ended
Term ended Sep 30, 2023 · Medium confidence
Term endedTerm ended Sep 30, 2023Medium confidence
US 7,220,356Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Formerly held
Term ended
Term ended Sep 12, 2023 · High confidence
Term endedTerm ended Sep 12, 2023High confidence
US 7,582,299Cripto-Specific Antibodies
Formerly held
Term ended
Ended no later than Aug 31, 2023 · Low confidence
Term endedEnded no later than Aug 31, 2023Low confidence
US 7,319,139TAG-72 specific CH2 domain deleted antibodies
Formerly held
Term ended
Term ended Jan 29, 2022 · From the USPTO record
Term endedTerm ended Jan 29, 2022From the USPTO record
US 8,329,172Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
Formerly held
Term ended
Term ended Nov 15, 2021 · From the USPTO record
Term endedTerm ended Nov 15, 2021From the USPTO record
US 7,604,989Inhibition of apoptosis process and improvement of cell performance
Lapsed on the fee record
Ended Oct 20, 2021 · From the USPTO record
Lapsed on the fee recordEnded Oct 20, 2021From the USPTO record
10 of 96 patents shown.
Pro members see all 96.
Pro members: see all 96 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited